

Obesity and Onset of Significant Depressive Symptoms: Results From a Prospective Community-Based Cohort Study of Older Men and Women

Nicole Vogelzangs, MSc; Stephen B. Kritchevsky, PhD; Aartjan T. F. Beekman, MD, PhD; Gretchen A. Brenes, MD, PhD; Anne B. Newman, MD, PhD; Suzanne Satterfield, MD, DrPh; Kristine Yaffe, MD; Tamara B. Harris, MD, MS; and Brenda W. J. H. Penninx, PhD; for the Health ABC Study

Objective: Although several cross-sectional studies have linked obesity and depression, less is known about their longitudinal association and about the relative influence of obesity subtypes. We prospectively examined whether obesity (specifically, abdominal) increased the risk of onset of depression in a population-based sample of older persons.

Method: Participants were 2,547 nondepressed, well-functioning white and black persons, aged 70–79 years, enrolled in the Health, Aging, and Body Composition Study, an ongoing prospective community-based cohort study. Baseline measurements were conducted between April 1997 and June 1998. Overall obesity was assessed by body mass index (BMI) and percent body fat (measured by dual energy x-ray absorptiometry), whereas abdominal obesity measures included waist circumference, sagittal diameter, and visceral fat (measured by computer tomography). Onset of significant depressive symptoms was defined as a Center for Epidemiologic Studies Depression 10-item score ≥ 10 at any annual follow-up over 5 years and/or new antidepressant medication use. Persistent depression was defined as depression at 2 consecutive follow-up visits.

Results: Over 5 years, significant depressive symptoms emerged in 23.7% of initially nondepressed persons. In men, both overall (BMI: hazard ratio [HR] per SD increase = 1.20; 95% CI, 1.03–1.40) and abdominal obesity (visceral fat: HR per SD increase = 1.19; 95% CI, 1.07–1.33) predicted onset of depressive symptoms after adjustment for sociodemographics. When BMI and visceral fat were adjusted for each other, only visceral fat was significantly associated with depression onset (HR = 1.18; 95% CI, 1.04–1.34). Stronger associations were found for persistent depressive symptoms. No associations were found in women.

Conclusion: This study shows that obesity, in particular visceral fat, increases the risk of onset of significant depressive symptoms in men. These results suggest that specific mechanisms might relate visceral fat to the onset of depression.

J Clin Psychiatry 2010;71(4):391–399

© Copyright 2009 Physicians Postgraduate Press, Inc.

Submitted: September 25, 2008; **accepted:** January 2, 2009.

Online ahead of print: December 15, 2009

(doi:10.4088/JCP.08m04743blu).

Corresponding author: Nicole Vogelzangs, MSc, Department of Psychiatry and the EMGO Institute for Health and Care Research, VU University Medical Center, AJ Ernststraat 887, 1081 HL Amsterdam, Netherlands (n.vogelzangs@ggzingeest.nl).

In a recent systematic review of epidemiologic studies, Atlantis and Baker¹ concluded there is a weak level of evidence that obesity increases the incidence of depression, predominantly based on cross-sectional studies.^{2–4} The prevalence of overweight and obesity is increasing worldwide at an alarming rate.⁵ In the United States, obesity is prevalent among almost one-third of the general population, and another third is overweight.⁶ Overweight and obesity are associated with a multitude of health risks, including increased risks of diabetes and cardiovascular disease (CVD).^{7,8} This combination of high prevalence and poor outcomes makes obesity a major public health concern with implications for depression outcomes, as well. At this moment, however, depression guidelines do not consider obesity as a major comorbidity of depression. Before obesity comorbidity can be incorporated in depression treatment, it is important to gain more knowledge of the direction, specifics, and strength of the association between obesity and depression.

Longitudinal studies that examine the direction of the association between depression and obesity are relatively sparse, were mostly conducted among adolescents, and show mixed results. Recently, we showed that depression is associated with an increase in obesity over time.⁹ Conversely, one study showed that obesity was associated with subsequent depression,¹⁰ but this was not confirmed in another study.¹¹ In addition, sex inconsistencies in the obesity-depression relationship have been found.^{1–3,11,12} Furthermore, different subtypes of obesity exist, and the location of excess fat storage may be an important determinant of subsequent health risks. Excess fat in the visceral region has been found to be a stronger predictor of diabetes and CVD than overall obesity.^{13,14} Longitudinal

studies on the association between abdominal obesity and depression are even more sparse.

The present study investigated prospectively whether obesity predicted the onset of significant depressive symptoms in an older sample of initially nondepressed persons. In addition, this study examined whether the association between obesity and onset of depressive symptoms was consistent for men and women and whether type of obesity (overall vs abdominal) influenced the obesity-depression link.

METHOD

Study Population

The Health, Aging, and Body Composition (Health ABC) study is an ongoing prospective cohort study among 3,075 well-functioning white and black men and women, aged 70–79 years. The Health ABC study was designed to prospectively investigate changes in body composition and weight-related health outcomes in an aging population. Participants were recruited between April 1997 and June 1998 from a random sample of white and black Medicare-eligible beneficiaries residing in the areas surrounding Pittsburgh, Pennsylvania and Memphis, Tennessee. Eligible subjects reported no difficulty with walking for a quarter of a mile, walking up 10 steps, or performing activities of daily living. Subjects were ineligible if they had severe difficulty communicating, active cancer treatment in the past 3 years, or plans to move. After complete description of the study, all participants signed an informed written consent approved by the institutional review boards of the clinical sites. For the present study, only persons free of depression at baseline were selected (N = 2,802). Of these, persons without data on baseline BMI or visceral fat (n = 104) or with no follow-up data on depressive symptoms (n = 151) were excluded, leaving 2,547 persons for the present analyses. Excluded persons were more often men (57.6% vs 48.6%, $P = .006$), black (52.2% vs 40.6%, $P < .001$), were less educated (35.7% vs 43.6% with postsecondary education; $P < .001$), had more often onset of depressive symptoms (33.7% vs 23.9%, $P = .03$), and had a lower (sex-adjusted) percent body fat (33.7% vs 35.1%, $P = .002$) than included persons, but did not differ in age or other obesity measures.

Significant Depressive Symptoms

During the baseline interview and at follow-up (after 2, 3, 4, and 5 years), depressive symptoms were measured with the Center for Epidemiologic Studies Depression (CES-D) scale 10-item version, assessing depressive symptoms in the previous week.¹⁵ The original 20-item CES-D scale has been widely used in older populations and has been shown to be a valid and reliable instrument (100% sensitivity and 88% specificity for detecting a major depressive disorder in the older population),¹⁶ but the 10-item subset of the CES-D, ranging from 0 to 30, has shown good predictive accuracy when compared to the 20-item CES-D scale.¹⁷ In addition, at

baseline and at follow-up (after 1, 2, 4, and 5 years), all medications regularly taken in the past 2 weeks were recorded and coded according to the Iowa Drug Information System (IDIS).¹⁸ Antidepressant use included monoamine oxidase inhibitors (281605), tri/tetracyclic antidepressants (281606), selective serotonin reuptake inhibitors (281607), and other antidepressants (281604) with depression or mood disorder as self-reported reason. Persons with antidepressant use or a CES-D-10 score ≥ 10 (compares to the commonly used cut-off of ≥ 16 on CES-D-20¹⁷) at baseline were excluded from the analyses. For the present analyses, onset of significant depressive symptoms was defined as having a CES-D-10 score ≥ 10 on any of the follow-up assessments and/or new antidepressant medication use during follow-up. To identify the onset of more chronic depressive symptoms, persistent depressive symptoms were defined as depressive symptoms at 2 consecutive follow-up visits. For sensitivity analyses, 2 alternative definitions of depressive symptoms were constructed: one based on CES-D-10 scores only (since antidepressant medications are sometimes used in the treatment of obesity), and another that incorporated an additional requirement of a minimum increase of 3 points on the CES-D-10 (to assure an actual onset of depressive symptoms and not just a crossing of the cut-off point).

Obesity

Overall obesity. Body weight was measured on a standard balance beam scale to the nearest 0.1 kg. Height was measured barefoot using a wall-mounted stadiometer to the nearest 0.1 cm. Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m^2). Body mass index categories were constructed to indicate normal weight ($BMI < 25$), overweight ($BMI \geq 25$ and < 30), and obesity ($BMI \geq 30$). Percent body fat was determined via a whole body dual energy x-ray absorptiometry (DXA) scan (for details, see Vogelzangs et al⁹).

Abdominal obesity. Computed tomography (CT) scanning was performed at the level between the fourth and fifth lumbar vertebrae (L4–L5) to measure visceral fat (cm^2), as described in Vogelzangs et al.⁹ Next to this continuous measure of visceral fat, sex-specific quartiles of visceral fat were constructed, and a dichotomous visceral fat variable compared persons in the highest quartile to persons in quartiles 1 to 3. In addition to this direct CT measure of visceral fat, some anthropometric measures were assessed. Maximum sagittal diameter (cm), the distance between the abdomen and back, was derived from the CT scans. Waist circumference (cm) was measured at the largest abdominal circumference to the nearest 0.1 cm using a flexible plastic tape measure.

Covariates

Covariates were a priori selected on the basis of previously reported associations with both obesity and depression. Sociodemographic characteristics included age,

sex, site (Pittsburgh, Memphis), race (white, black), marital status (yes or no currently married), and education (less than high school, high school, postsecondary). Lifestyle characteristics were also assessed, including smoking status (non, former, or current), current alcohol use (yes or no > 1 drink per day), and physical activity (sum of weight training, high and medium intensity exercise, aerobic dance, [exercise] walking, and stair climbing [in kcal/wk]). As both obesity (specifically, abdominal) and depression have consistently been associated with CVD and diabetes, these diseases were specifically addressed. Presence of baseline diabetes and CVD (including stroke, myocardial infarction, angina pectoris, coronary angioplasty, or coronary artery bypass grafting) was adjudicated using standardized algorithms, considering various sources of information that included self-report, medication use, clinical examination findings, and medical claims data from the former Health Care Financing Administration. Identification of incident diabetes and new CVD events during follow-up additionally included hospitalization records assessed according to set algorithms. Also, we included 2 indicators for general health status. Number of other chronic diseases was mainly based on self-report and included congestive heart failure, peripheral arterial disease, cancer, lung disease, osteoarthritis, osteoporosis, gastrointestinal disease, prostate disease, thyroid disease, Parkinson's disease, and kidney disease. In addition, all medications regularly taken in the past 2 weeks before baseline were recorded and coded according to the Iowa Drug Information System (IDIS).¹⁸ From this inventory, the total number of prescription medications taken was calculated.

Statistical Analyses

Because sex differences in the relationship between obesity and depression have been observed,^{3,12} and since men and women differ in body composition, all analyses were presented for men and women separately, and sex-interaction effects were tested for statistical significance. Sample characteristics were compared between persons with and without onset of depressive symptoms during follow-up using χ^2 tests for dichotomous and categorical variables and independent *t* tests for continuous variables. Risk of onset of significant depressive symptoms (overall, nonpersistent and persistent) according to different measures of obesity (overall and abdominal) was assessed using Cox regression analyses, and the proportional hazards assumption was examined. The assumption of linearity was assessed by checking improvement of model fit after inclusion of a quadratic term for each corresponding obesity measure, respectively. Presence of multicollinearity was assessed by means of the variance inflation factor (VIF) when all covariates were included in the same model. To be able to compare hazard ratios (HRs) across obesity measures, HRs with 95% confidence intervals (CIs) were expressed per standard deviation (SD) increase. For comparability across

subsamples, sex-weighted SDs were used. Analyses were adjusted for baseline CES-D-10 score, sex, age, race, site, marital status, and education. Because fat distribution differs between whites and blacks, all analyses were repeated, including race-interaction terms, to test whether findings were consistent across race.

To examine whether associations between obesity and onset of significant depressive symptoms could be explained by lifestyle or disease differences at baseline, the above described Cox regression analyses were additionally adjusted for smoking, alcohol use, physical activity, prevalent and incident diabetes and CVD, number of other chronic diseases, and number of prescription medication taken. In order to compare the independent effects of overall and abdominal obesity, the associations between overall obesity measures and onset of depressive symptoms were adjusted for visceral fat, and the associations between abdominal obesity measures and onset of depression were adjusted for BMI.

Finally, the risks of onset of depressive symptoms and of persistent depressive symptoms were plotted for men and women across BMI categories and for men and women with high versus normal visceral fat mass, and onset rates of depressive symptoms were calculated (in percent per year). In addition, population attributable risks (PARs) of obesity ($BMI \geq 30$) and high visceral fat ($\geq 194 \text{ cm}^2$) in men were calculated. Population attributable risk describes the percentage by which the onset rate of depressive symptoms or persistent depressive symptoms could be reduced when the risk factor would be completely eliminated. The following equation was used: $\text{PAR} = p(\text{HR} - 1) / (1 + p[\text{HR} - 1])$, where p is the prevalence of the risk factor in the population at risk.¹⁹

RESULTS

The mean age of the participants was 73.6 ($SD = 2.9$) years, 51.4% were women, and 40.6% were black. During a mean follow-up of 4.3 ($SD = 1.1$) years, significant depressive symptoms emerged in 23.9% ($n = 609$) of the initially nondepressed sample and significant persistent depressive symptoms in 7.8% ($n = 198$). Men experienced more diabetes and CVD, but women had a higher rate of onset of depressive symptoms. The mean BMI was comparable between men and women, however women had a higher percent body fat (40.7% vs 29.3%) than men, but had less visceral fat (132.2 vs 155.2 cm^2). Visceral fat correlated more strongly with waist circumference (Pearson's $r = .65$) and sagittal diameter (Pearson's $r = .75$) than with BMI (Pearson's $r = .56$). Table 1 shows sample characteristics for persons with and without onset of depressive symptoms during follow-up for men and women separately.

Table 2 shows the results of Cox regression analyses assessing the risk of onset of significant depressive symptoms according to baseline obesity among nondepressed

Table 1. Sample Characteristics for Men and Women With and Without Onset of Depressive Symptoms During Follow-Up

Variable	Men			Women		
	No Depressive Symptoms During Follow-Up (n = 988)	Depressive Symptoms During Follow-Up (n = 250)	P ^a	No Depressive Symptoms During Follow-Up (n = 950)	Depressive Symptoms During Follow-Up (n = 359)	P ^a
Sociodemographic						
Age, mean (SD), y	73.6 (2.9)	73.9 (2.8)	.22	73.5 (2.9)	73.5 (2.9)	.90
Black, %	33.7	44.0	.002	43.9	48.7	.12
Memphis site, %	47.1	52.4	.13	49.4	53.2	.22
Married, %	73.0	65.6	.02	39.7	39.6	.97
Educational level, %			<.001			<.001
Less than high school	22.9	35.6		19.8	28.1	
High school	26.5	21.6		38.2	42.6	
Postsecondary	50.6	42.8		42.0	29.2	
Lifestyle						
Smoking, %			.87			.28
Never	30.9	29.2		56.8	61.6	
Former	59.2	60.4		34.5	30.1	
Current	9.9	10.4		8.6	8.4	
>1 alcoholic drink/d, %	12.9	8.8	.08	3.7	2.8	.43
Physical activity, mean (SD), kcal/wk	1,539 (2,514)	1,215 (1,879)	.02	743 (1,240)	649 (1,309)	.23
Health and disease						
Prevalent cardiovascular disease, %	28.1	29.2	.74	16.9	23.7	.005
Prevalent diabetes, %	25.7	28.4	.39	17.9	24.8	.005
New cardiovascular event during follow-up, %	16.5	11.6	.06	8.4	9.5	.55
Incident diabetes during follow-up, %	4.6	5.2	.67	4.9	2.8	.09
No. of other chronic diseases, mean (SD)	1.4 (1.0)	1.5 (1.1)	.24	0.9 (0.9)	1.2 (1.0)	<.001
No. of prescription medications taken, mean (SD)	2.8 (2.4)	3.2 (2.7)	.02	3.0 (2.5)	3.8 (2.8)	<.001
Depression-related						
Baseline CES-D-10 score (0–30), mean (SD)	1.9 (2.1)	3.5 (2.6)	<.001	2.3 (2.3)	3.8 (2.6)	<.001
Onset of persistent depressive symptoms, %	NA	30.0	NA	NA	34.3	NA
Obesity						
Overall obesity						
Body mass index, mean (SD), kg/m ²	27.0 (3.7)	27.5 (4.3)	.09	27.7 (5.4)	27.9 (5.4)	.52
Percent body fat, mean (SD)	29.2 (4.7)	29.7 (5.4)	.14	40.7 (5.6)	40.6 (5.9)	.87
Abdominal obesity						
Waist circumference, mean (SD), cm	100.7 (10.3)	102.3 (11.3)	.04	97.9 (13.4)	99.0 (13.8)	.22
Sagittal diameter, mean (SD), cm	23.6 (3.2)	24.2 (3.5)	.01	23.4 (3.5)	23.6 (3.5)	.28
Visceral fat, mean (SD), cm ²	153.0 (68.8)	163.8 (78.7)	.05	131.8 (61.1)	133.4 (59.9)	.66

^aBased on χ^2 test for dichotomous and categorical variables and independent *t* test for continuous variables.

Abbreviations: CES-D-10 = Center for Epidemiologic Studies Depression scale 10-item version, NA = not applicable.

persons at baseline. In the total sample, no associations were found for overall obesity measures, but sagittal diameter (HR per SD [3.4 cm] increase = 1.11; 95% CI, 1.02–1.20) and visceral fat (HR per SD [65.5 cm²] increase = 1.10; 95% CI, 1.02–1.20) predicted onset of depressive symptoms after adjustment for sociodemographics. Sex-stratified analyses showed that both overall and abdominal obesity increased the risk of onset of depressive symptoms in men. For instance, risk of depressive symptoms increased by 20% for each SD (4.6 kg/m²) increase in BMI (HR = 1.20; 95% CI, 1.03–1.40) and by 19% for each SD (65.5 cm²) increase in visceral fat (HR = 1.19; 95% CI, 1.07–1.33) (Table 2). No associations were found in women. When tested, obesity by sex interactions were found (BMI, *P* = .04; percent body fat, *P* = .03; waist circumference, *P* = .04; sagittal diameter, *P* = .04; visceral fat, *P* = .06). No significant obesity by race interactions were observed among men and women (all

P > .20). Similar results were found when the definition of the onset of depressive symptoms was determined without data on new antidepressant use (n with depression = 553) or when an additional requirement of a minimum 3-point increase on the CES-D-10 was incorporated (n with depression = 593). Persons with significant depressive symptoms at follow-up (based on CES-D-10) increased from a mean baseline CES-D-10 score of 3.7 (SD = 2.6) to a mean CES-D-10 score of 12.4 (SD = 2.8) during their depressed episodes. As can be seen in Table 2, additional adjustment for smoking, alcohol use, physical activity, prevalent and incident diabetes and CVD, number of other chronic diseases, and number of prescription medication taken did not change the results in any meaningful way.

Next, to assess the effect of abdominal obesity versus overall obesity, the associations between overall obesity measures and onset of significant depressive symptoms

Table 2. Risk (per SD Increase^a) of Onset of Significant Depressive Symptoms Among Initially Nondepressed Persons According to Baseline Obesity

Variable	Unadjusted Risk ^b			Risk Adjusted for Sociodemographics ^c			Risk Additionally Adjusted for Lifestyle and Diseases ^d			Risk Additionally Adjusted for Obesity ^e		
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Total sample (N = 2,547)												
Overall obesity												
Body mass index	1.06	0.99–1.15	.11	1.04	0.96–1.12	.32	1.02	0.94–1.10	.71	0.96	0.87–1.06	.41
Percent body fat	1.03	0.95–1.12	.42	1.04	0.96–1.13	.34	1.02	0.94–1.11	.58	0.98	0.89–1.08	.68
Abdominal obesity												
Waist circumference	1.11	1.03–1.20	.01	1.08	0.99–1.17	.07	1.05	0.97–1.14	.27	1.10	0.95–1.27	.19
Sagittal diameter	1.14	1.05–1.23	.002	1.11	1.02–1.20	.02	1.08	0.99–1.17	.09	1.23	1.05–1.43	.01
Visceral fat	1.10	1.02–1.19	.02	1.10	1.02–1.20	.02	1.07	0.99–1.17	.09	1.10	0.99–1.22	.06
Men (n = 1,238)												
Overall obesity												
Body mass index	1.18	1.01–1.37	.03	1.20	1.03–1.40	.02	1.18	1.01–1.37	.04	1.10	0.93–1.32	.27
Percent body fat	1.14	0.99–1.31	.08	1.19	1.03–1.36	.02	1.15	1.00–1.33	.05	1.10	0.94–1.28	.22
Abdominal obesity												
Waist circumference	1.20	1.04–1.39	.01	1.23	1.06–1.42	.006	1.20	1.04–1.39	.01	1.26	1.04–1.52	.02
Sagittal diameter	1.24	1.09–1.40	.001	1.24	1.08–1.41	.001	1.21	1.06–1.38	.004	1.31	1.11–1.56	.002
Visceral fat	1.16	1.04–1.29	.01	1.19	1.07–1.33	.002	1.17	1.04–1.31	.009	1.18	1.04–1.34	.009
Women (n = 1,309)												
Overall obesity												
Body mass index	1.03	0.94–1.12	.54	0.99	0.91–1.08	.84	0.97	0.88–1.06	.47	0.93	0.83–1.03	.16
Percent body fat	0.99	0.90–1.09	.82	0.97	0.88–1.07	.55	0.96	0.87–1.06	.45	0.93	0.84–1.04	.20
Abdominal obesity												
Waist circumference	1.07	0.98–1.18	.14	1.02	0.92–1.12	.74	0.99	0.90–1.09	.80	1.04	0.89–1.21	.66
Sagittal diameter	1.08	0.98–1.20	.13	1.03	0.93–1.15	.53	1.00	0.90–1.11	.98	1.12	0.93–1.34	.23
Visceral fat	1.05	0.94–1.18	.37	1.03	0.92–1.15	.64	1.00	0.89–1.12	.93	1.02	0.88–1.17	.83

^aSD = 4.6 kg/m² for body mass index, 5.3% for percent body fat, 12.0 cm for waist circumference, 3.4 cm for sagittal diameter, and 65.5 cm² for visceral fat.

^bBased on Cox regression analyses adjusted for sex (total sample only).

^cAdditionally adjusted for baseline CES-D-10 score, age, race, site, marital status, and educational level.

^dAdditionally adjusted for smoking, alcohol use, physical activity, prevalent diabetes or CVD, incident diabetes, new CVD events, number of other chronic diseases, and number of prescription medications taken.

^eAdditionally adjusted for visceral fat (overall obesity only) and body mass index (abdominal obesity only).

Abbreviations: CES-D-10 = Center for Epidemiologic Studies Depression scale 10-item version, CVD = cardiovascular disease, HR = hazard ratio.

were adjusted for visceral fat and were found to be no longer significant in men (eg, for BMI: HR = 1.10; 95% CI, 0.93–1.32; Table 2). Alternatively, when associations between abdominal obesity and onset of depressive symptoms in men were adjusted for BMI, the associations remained similar (eg, for visceral fat: HR = 1.18; 95% CI, 1.04–1.34; Table 2). Table 3 presents fully adjusted models (with and without adjustment for obesity) with onset of nonpersistent depressive symptoms and persistent depressive symptoms as the outcome. Although associations of abdominal obesity with onset of nonpersistent depressive symptoms were found, obesity was more strongly associated with the more chronic indicator of depressive symptoms in men; in women, associations remained absent. When tested, no indications of nonlinearity or multicollinearity were found (all quadratic terms $P > .05$; all VIF < 2).

To graphically illustrate the association between obesity and onset of both depressive symptoms and persistent depressive symptoms, the cumulative onset of depressive symptoms over time adjusted for sociodemographics, lifestyle, and diseases was plotted for men and women across BMI categories (Figure 1A and 1C) and for men and women with normal (Q1–Q3) and high (Q4) visceral fat (Figure

1B and 1D). In addition, unadjusted onset rates of depressive symptoms across groups are presented in Figure 1. Obese men (BMI > 30) were at the highest risk for onset of depressive symptoms, which was statistically significant for persistent depressive symptoms (HR = 2.03; 95% CI, 1.06–3.89). Men with high visceral fat (≥ 194 cm²) had a 1.33 increased risk (95% CI, 1.00–1.77) of becoming depressed and a 2.04 increased risk (95% CI, 1.25–3.34) of becoming persistently depressed compared to men with visceral fat < 194 cm². As can be seen from Figure 1, men with high visceral fat were at an equal risk of becoming depressed than women in general. In fact, the unadjusted hazard ratio of onset of depressive symptoms for women compared to men was 1.38 (95% CI, 1.17–1.62) and 1.62 (95% CI, 1.22–2.16) for onset of persistent depressive symptoms, which is equal to or even lower than the hazard ratios of onset of depressive symptoms and persistent depressive symptoms due to high visceral fat in men. High BMI or visceral fat did not increase the risk of becoming depressed in women. Finally, the population attributable risks of BMI > 30 and high visceral fat adjusted for sociodemographics, lifestyle, and diseases were calculated for men and found to be 7% and 8%, respectively, for onset of depressive symptoms and 17%

Table 3. Risk (per SD Increase^a) of Onset of Significant Nonpersistent and Persistent Depressive Symptoms Among Initially Nondepressed Persons According to Baseline Obesity

Variable	Nonpersistent Depressive Symptoms (Men: n = 175; Women: n = 236)						Persistent Depressive Symptoms (Men: n = 75; Women: n = 123)					
	Risk Adjusted for Lifestyle and Diseases ^b			Risk Additionally Adjusted for Obesity ^c			Risk Adjusted for Lifestyle and Diseases ^b			Risk Additionally Adjusted for Obesity ^c		
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Men (n = 1,238)												
Overall obesity												
Body mass index	1.07	0.89–1.29	.49	1.03	0.83–1.28	.76	1.50	1.13–1.98	.005	1.29	0.94–1.76	.12
Percent body fat	1.05	0.89–1.25	.54	1.03	0.85–1.24	.76	1.50	1.16–1.95	.002	1.37	1.04–1.82	.03
Abdominal obesity												
Waist circumference	1.12	0.94–1.34	.20	1.23	0.99–1.54	.07	1.46	1.12–1.92	.006	1.41	1.01–1.96	.05
Sagittal diameter	1.14	0.97–1.33	.11	1.27	1.04–1.56	.02	1.43	1.12–1.83	.004	1.47	1.08–2.01	.01
Visceral fat	1.08	0.94–1.25	.27	1.10	0.94–1.29	.22	1.40	1.17–1.68	<.001	1.42	1.17–1.73	<.001
Women (n = 1,309)												
Overall obesity												
Body mass index	0.96	0.86–1.07	.47	0.94	0.82–1.07	.35	0.96	0.81–1.12	.58	0.86	0.72–1.04	.12
Percent body fat	0.95	0.84–1.07	.40	0.93	0.82–1.07	.31	0.98	0.82–1.16	.80	0.91	0.76–1.11	.35
Abdominal obesity												
Waist circumference	1.00	0.88–1.12	.96	1.10	0.91–1.34	.32	0.94	0.80–1.11	.47	0.90	0.69–1.18	.45
Sagittal diameter	1.00	0.87–1.14	.95	1.17	0.93–1.46	.18	0.99	0.82–1.19	.88	1.03	0.74–1.42	.87
Visceral fat	0.97	0.84–1.12	.64	0.99	0.84–1.18	.94	1.02	0.84–1.23	.86	1.05	0.83–1.32	.71

^aSD = 4.6 kg/m² for body mass index, 5.3% for percent body fat, 12.0 cm for waist circumference, 3.4 cm for sagittal diameter, and 65.5 cm² for visceral fat; persons with persistent depressive symptoms were excluded from the analyses on nonpersistent depressive symptoms and persons with nonpersistent depressive symptoms were excluded from the analyses on persistent depressive symptoms.

^bBased on Cox regression analyses adjusted for baseline CES-D-10 score, age, race, site, marital status, educational level, smoking, alcohol use, physical activity, prevalent diabetes or CVD, incident diabetes, new CVD events, number of other chronic diseases, and number of prescription medications taken.

^cAdditionally adjusted for visceral fat (overall obesity only) and body mass index (abdominal obesity only).

Abbreviations: CES-D-10 = Center for Epidemiologic Studies Depression scale 10-item version, CVD = cardiovascular disease, HR = hazard ratio.

and 19% for onset of persistent depressive symptoms. This suggests that in the entire older male population, 19% of all new cases with persistent depressive symptoms were related to having high visceral fat mass.

DISCUSSION

This study examined whether obesity was associated with onset of significant depressive symptoms in a large community-based sample of older, initially nondepressed persons during 5 years of follow-up. The results showed that in men, but not in women, obesity increased the risk of onset of significant depressive symptoms. Specifically, abdominal obesity appeared to be associated with the onset of depressive symptoms, independent of and more consistently than overall obesity. Men with high visceral fat had a more than 2-fold increased risk of becoming persistently depressed compared to men with normal amounts of visceral fat. Moreover, results showed that in men, almost 10% of the onsets of depressive symptoms and 20% of the onsets of persistent depressive symptoms were related to having high visceral fat.


Several studies indicated that obesity and depression are associated.^{2–4} However, as concluded by Atlantis and Baker¹ in their systematic review on obesity and depression, few studies have investigated the temporal direction of this association. Our findings correspond to a study by Roberts et al,¹⁰ which showed among persons aged ≥50 years that obesity at baseline was associated with an increased risk of

depression 5 years later. Our results additionally showed that associations with depressive symptoms appear to be more consistently related to abdominal obesity than to overall obesity. The association between depressive symptoms and overall obesity in men was not consistently found after adjustment for visceral fat, while the association with visceral fat remained after controlling for BMI. At least, these results show that abdominal obesity has an additional effect on onset of depressive symptoms above the influence of overall obesity. These results are in line with other studies showing that, in particular, abdominal obesity, more than overall obesity, is associated with poor health outcomes, such as diabetes and CVD.^{13,14}


To our knowledge, the current study was the first to test and demonstrate that abdominal obesity increases the risk of onset of significant depressive symptoms in men. This evidence should be considered together with other recent longitudinal results that illustrate—the other way around—that depressive symptoms also lead to increases in abdominal obesity over 5 years.⁹ The fact that abdominal obesity and depressive symptoms are found to be reciprocally associated indicates that the 2 are strongly intertwined and suggests that a vicious cycle might exist. The bidirectional relationship between abdominal obesity and depressive symptoms further indicates that when trying to break this vicious cycle, treatment of either obesity or depression cannot be given in isolation and comorbidity between these 2 should be taken into consideration.

Figure 1. Cumulative Onset of Depressive Symptoms and Persistent Depressive Symptoms According to Sex, Body Mass Index Categories, and Visceral Fat Status^a


A. Cumulative Onset of Depressive Symptoms According to Sex and Body Mass Index




B. Cumulative Onset of Depressive Symptoms According to Sex and Visceral Fat



C. Cumulative Onset of Persistent Depressive Symptoms According to Sex and Body Mass Index



D. Cumulative Onset of Persistent Depressive Symptoms According to Sex and Visceral Fat



^aPersons with nonpersistent depressive symptoms were excluded from the persistent depressive symptoms analyses.

^bUnadjusted rates.

^cBased on Cox regression analyses adjusted for baseline CES-D-10 score, age, race, site, marital status, educational level, smoking, alcohol use, physical activity, prevalent diabetes or CVD, incident diabetes, new CVD events, number of other chronic diseases, and number of prescription medications taken.

Abbreviations: CES-D-10 = Center for Epidemiologic Studies Depression scale 10-item version, CVD = cardiovascular disease.

How might abdominal obesity increase the risk of incident depression? First, a poor self-image or perceived stigma of an obese person might induce depression.²⁰ Also, binge-eating behavior, not uncommon in obese persons, has been associated with major depressive disorder.²¹ These mechanisms are probably true for overall obesity as well as and not specific for abdominal obesity. Poor lifestyle behaviors might lead to both abdominal obesity and depression. However, in our analyses, adjustment for lifestyle behaviors

did not influence results much. In addition, diseases related to abdominal obesity such as diabetes and CVD have been associated with depression^{22,23} and might be responsible for the association between abdominal obesity and depression. In our study, adjustment for prevalent as well as incident diabetes and CVD did not affect the relationship between abdominal obesity and the onset of depressive symptoms, suggesting that such an association does exist rather independent of diabetes and CVD. Other pathophysiological

explanations may exist. Studies have shown that visceral fat produces cytokines in higher amount than subcutaneous fat.²⁴ High levels of cytokines such as TNF- α , IL-6, and C-reactive protein have been found both in visceral obesity²⁵ and depression.²⁶ In addition, the mechanisms discussed above (poor lifestyle, more diabetes and CVD, and inflammation in obese persons) might all induce vascular damage and are, therefore, in line with the vascular depression hypothesis, which states that vascular damage in the brain might predispose, precipitate, or perpetuate depression in the elderly.²⁷ Other linking mechanisms could be a dysregulation of the hypothalamic-pituitary-adrenal axis^{28,29} or a diminished functioning of sex steroid hormones^{30,31} as these mechanisms have been linked to both abdominal obesity and depression.

The link between abdominal obesity and significant depressive symptoms was restricted to men. A reason for this could be due to the fact that men have more visceral fat than women. If the amount of visceral fat is important for negative health effects to emerge, than men will be more at risk to experience such negative health effects. In addition, this is an aging population in which losses of fat (including visceral fat) over time are not uncommon, especially in women,³² which might leave women at a smaller risk of having visceral fat cause poor health. Another explanation might be that, in women, the relative contribution of visceral fat to depression onset is small due to a larger influence of competing risk factors. For instance, insufficient social support and stressful life events have been found to pose a greater risk for depression among women compared to men.^{33,34} Although previous cross-sectional studies that examined sex differences predominantly showed stronger results for women in the association between overall obesity and depression,^{3,12} one study reported an association between depression and abdominal obesity only in men.² Future research should explore these sex differences further in younger samples to eliminate counteracting effects of aging.

Our study had some limitations. We did not have well-defined *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (DSM-IV)³⁵-based depression diagnoses. However, the CES-D is a commonly used scale to assess clinically significant depressive symptoms. In addition, since we had no information on history of depression, onset of depressive symptoms might represent recurrence of an earlier depression in life. Therefore, results do not necessarily indicate incidence of a first depression episode in life, which is less common in later life, but do reflect a new occurrence of depressive symptoms during later life. Our study also had some important strengths, including a large sample with longitudinal assessments of depressive symptoms. In addition, DXA and CT scans were performed, which assess total and visceral fat stores directly, and we were able to compare them with more commonly used anthropometric measures.

In all, our findings indicate that the strength of the association between abdominal obesity and depressive symptoms is of both clinical and public health relevance. Men with visceral fat levels in the highest quartile ($\geq 194 \text{ cm}^2$) had almost a 35% greater chance of becoming depressed over 5 years than men with normal amounts of visceral fat. The risk of becoming persistently depressed was more than 2-fold for men with high visceral fat. We found that the size of this effect was at least equal to the difference in the onset rate of depressive symptoms between men and women. A 35%–40% increased risk of incident depression for women versus men is comparable to what has been found in other studies among older persons³⁶ and is normally considered to be an important predictor for depression onset. In contrast to sex, however, high visceral fat is potentially modifiable, and it is tempting to consider the possibility that weight reduction might reduce the onset of new depressive symptoms. Future research should investigate whether visceral fat reduction indeed can prevent onset of depressive symptoms.

In conclusion, our results suggest that, in older men, obesity relates to the onset of significant depressive symptoms. Abdominal obesity appears to be more consistently associated with onset of depressive symptoms than overall obesity or at least shows an additional effect above overall obesity. These findings strengthen the idea that specific properties of visceral fat might give rise to depression. The impact of the association between abdominal obesity and onset of significant depressive symptoms on public mental health seems to be of great enough importance to warrant additional research that confirms our findings and explores underlying mechanisms. When these mechanisms are known, this might have direct implications for depression treatment and prevention.

Author affiliations: Department of Psychiatry and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands (Drs Beekman and Penninx; Ms Vogelzangs); Sticht Center on Aging (Dr Kritchevsky) and Department of Psychiatry and Behavioral Medicine (Dr Brenes), Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania (Dr Newman); Department of Preventive Medicine, College of Medicine, University of Tennessee, Memphis (Dr Satterfield); Departments of Psychiatry, Neurology, and Epidemiology, University of California, San Francisco (Dr Yaffe); and Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Bethesda, Maryland (Dr Harris).

Potential conflicts of interest: None reported.

Funding/support: This work was supported by National Institute on Aging (NIA) contract numbers N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 and in part by the Intramural Research Program of the National Institutes of Health, NIA. Data analyses were supported by grant R01-HL72972-01 from the National Heart, Lung, and Blood Institute (NHLBI). The work of Ms Vogelzangs was supported by a travel grant from the Young Academy of the Royal Netherlands Academy of Arts and Science.

REFERENCES

1. Atlantis E, Baker M. Obesity effects on depression: systematic review of epidemiological studies. *Int J Obes (Lond)*. 2008;32(6):881–891.
2. Herva A, Laitinen J, Miettunen J, et al. Obesity and depression: results

from the longitudinal Northern Finland 1966 Birth Cohort Study. *Int J Obes (Lond)*. 2006;30(3):520–527.

3. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? results from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2003;158(12):1139–1147.
4. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. *Arch Gen Psychiatry*. 2006;63(7):824–830.
5. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic*. Geneva, Switzerland: World Health Organization; 2000. *Report of a WHO Consultation on Obesity*; vol 894.
6. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA*. 2006;295(13):1549–1555.
7. Harris TB, Launer LJ, Madans J, et al. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. *BMJ*. 1997;314(7097):1791–1794.
8. National Institutes of Health. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Washington, DC: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.
9. Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Depressive symptoms and change in abdominal obesity in older persons. *Arch Gen Psychiatry*. 2008;65(12):1386–1393.
10. Roberts RE, Deleger S, Strawbridge WJ, et al. Prospective association between obesity and depression: evidence from the Alameda County Study. *Int J Obes Relat Metab Disord*. 2003;27(4):514–521.
11. Forman-Hoffman VL, Yankey JW, Hillis SL, et al. Weight and depressive symptoms in older adults: direction of influence? *J Gerontol B Psychol Sci Soc Sci*. 2007;62(1):S43–S51.
12. Carpenter KM, Hasin DS, Allison DB, et al. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. *Am J Public Health*. 2000;90(2):251–257.
13. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. *BMJ*. 2001;322(7288):716–720.
14. Nicklas BJ, Penninx BWJH, Cesari M, et al. Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging, and Body Composition Study. *Am J Epidemiol*. 2004;160(8):741–749.
15. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. *Appl Psychol Meas*. 1977;1(3):385–401.
16. Beekman AT, Deeg DJ, Van Limbeek J, et al. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. *Psychol Med*. 1997;27(1):231–235.
17. Andresen EM, Malmgren JA, Carter WB, et al. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression scale). *Am J Prev Med*. 1994;10(2):77–84.
18. Pahor M, Chrischilles EA, Guralnik JM, et al. Drug data coding and analysis in epidemiologic studies. *Eur J Epidemiol*. 1994;10(4):405–411.
19. Smit F, Beekman A, Cuijpers P, et al. Selecting key variables for depression prevention: results from a population-based prospective epidemiological study. *J Affect Disord*. 2004;81(3):241–249.
20. Chen EY, Bocchieri-Ricciardi LE, Munoz D, et al. Depressed mood in class III obesity predicted by weight-related stigma. *Obes Surg*. 2007;17(5):669–671.
21. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. *Compr Psychiatry*. 2007;48(2):124–131.
22. Brown LC, Majumdar SR, Newman SC, et al. History of depression increases risk of type 2 diabetes in younger adults. *Diabetes Care*. 2005;28(5):1063–1067.
23. Penninx BW, Guralnik JM, Mendes de Leon CF, et al. Cardiovascular events and mortality in newly and chronically depressed persons > 70 years of age. *Am J Cardiol*. 1998;81(8):988–994.
24. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J Clin Endocrinol Metab*. 1998;83(3):847–850.
25. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha, and IL-6. *Diabetes Res Clin Pract*. 2005;69(1):29–35.
26. Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging, and Body Composition Study. *Biol Psychiatry*. 2003;54(5):566–572.
27. Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. *Arch Gen Psychiatry*. 1997;54(10):915–922.
28. Vogelzangs N, Suthers K, Ferrucci L, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. *Psychoneuroendocrinology*. 2007;32(2):151–159.
29. Weber-Hamann B, Hentschel F, Kniest A, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. *Psychosom Med*. 2002;64(2):274–277.
30. Björntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. *Int J Obes Relat Metab Disord*. 2000;24(suppl 2):S80–S85.
31. Morsink LF, Vogelzangs N, Nicklas BJ, et al. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. *Psychoneuroendocrinology*. 2007;32(8–10):874–883.
32. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging, and Body Composition Study. *Am J Clin Nutr*. 2005;82(4):872–878, quiz 915–916.
33. Kendler KS, Myers J, Prescott CA. Sex differences in the relationship between social support and risk for major depression: a longitudinal study of opposite-sex twin pairs. *Am J Psychiatry*. 2005;162(2):250–256.
34. Maciejewski PK, Prigerson HG, Mazure CM. Sex differences in event-related risk for major depression. *Psychol Med*. 2001;31(4):593–604.
35. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
36. Norton MC, Skoog I, Toone L, et al. Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study. *Am J Geriatr Psychiatry*. 2006;14(3):237–245.